Proxy Results (Form 8-K)

On August 26, 2025, Titan Pharmaceuticals, Inc. ("Titan" or the "Company") held a special meeting of stockholders (the "Special Meeting") for the purpose of voting on Titan's proposed business combination with Black Titan Corporation, a Cayman Islands exempted company limited by shares ("Black Titan") and TalenTec Sdn. Bhd., a Malaysia private limited company, f/k/a KE Sdn. Bhd. ("TalenTec"), as fully described in the joint proxy statement/prospectus (the "Proxy Statement") filed by the Company on July 22, 2025 (the "Merger").

The Special Meeting was held pursuant to notice on August 26, 2025 at the offices of Olshan Frome Wolosky LLP located at 1325 Avenue of the Americas, 15th Floor, New York, New York 10019. As of the record date, there were 1,330,234 shares of common stock outstanding and entitled to vote at the Annual Meeting. The total number of shares of common stock voted in person or by proxy at the Special Meeting was 734,135 shares, representing approximately 55.19% of the shares of common stock outstanding and entitled to vote at the Special Meeting.

At the Special Meeting, in connection with the Merger, Titan stockholders were asked to consider and vote upon the following proposals:

(1) The Business Combination Proposal - to approve and adopt the Merger and Contribution and Share Exchange Agreement, dated August 19, 2024 and the transactions contemplated thereby.

(2) The Nasdaq Proposal - to consider and vote upon a proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635, the issuance of Black Titan Ordinary Shares in connection with the Merger; and

(3) The Adjournment Proposal - to approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary.

As described below, each proposal was approved by the requisite vote of the Company's stockholders. The final voting results for each of the proposals submitted to a vote of the stockholders of the Company at the Special Meeting are set forth below. The proposals are described in detail in the Proxy Statement, and are incorporated herein by reference.

Proposal 1 - The Business Combination Proposal

Proposal 2 - The Nasdaq Proposal

Proposal 3 - The Adjournment Proposal

There were no broker non-votes for Proposals 1, 2 or 3.

Completion of the Merger remains subject to the satisfaction of other closing conditions as set forth in the Merger Agreement including, among other things, the approval of the listing of shares of Black Titan ordinary shares on The Nasdaq Stock Market.